Please assess the completion status of the following clinical trial:

Trial Title: A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be at least 18 years of age at screening~* Males and female patients with clinical diagnosis of ulcerative colitis ≥3 months prior to entry into the study.~* Male and female patients with active currently moderate to severe ulcerative colitis defined by Mayo score of ≥6~* Patients with endoscopic sub-score of ≥2 on the Mayo score determined within 7 days of baseline.~Exclusion Criteria:~* Diagnosis of Crohn's disease or diagnosis of indeterminate colitis~* Treatment naive subjects who have not had previous exposure to treatment for ulcerative colitis~* Patients that are currently receiving immunosuppressants, anti-TNFα therapy or interferon

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 15 mg BID (Type: EXPERIMENTAL): None
- 10 mg BID (Type: EXPERIMENTAL): None
- 3 mg BID (Type: EXPERIMENTAL): None
- 0.5 mg BID (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).